louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04050267: Effects of Low Concentrations of Nitrous Oxide
Official title: Effects of Low Concentrations of Nitrous Oxide on Cognitive Functions and Reaction Time
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nitrous Oxide Poisoning
Keywords: nitrous oxide
tracing gas
breathing experiments
cognitive tests
Lead sponsor: Czech Technical University in Prague
Sponsor class: OTHER
First posted: 2019-08-08
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: All participants go through all study arms, in random order.
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is to test the effects of low concentrations of nitrous oxide on cognitive functions and reaction time in human.

Detailed description: Nitrous oxide is a widely used gas in medicine, in standard concentrations above 50%. Its favourable physical properties and easy detectability by anaesthetic gas analysors predispose nitrous oxide to become a possible "tracing gas" for leak detection in experiments in which modified breathing system are in use. In these breathing experiments, the inspired concentrations of nitrous oxide would be well below the anaesthetic/analgesic concentrations. The aim of this study is to investigate the effects of these low concentrations of nitrous oxide (5, 7, 10, 12, 15, 20 %), compared to placebo (air, 0% nitrous oxide). The cognitive functions are tested using Digit Symbol Substitution Test, Reaction Time and Visual Analogue Scale.

Eligibility criteria: Inclusion Criteria:

* healthy volunteers from the Czech Technical University

Exclusion Criteria:

* pregnancy
* allergy to nitrous oxide
* severe asthma or other severe respiratory conditions
* severe cardiovascular conditions

Primary outcomes:
measure: Cognitive test results
timeFrame: Through study completion, an average of 1 year
measure: Reaction Time
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Praha
country: Czechia
facility: Czech Technical University
Study officials:
affiliation: Czech Technical University in Prague
name: Karel Roubik, prof., Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00685867: Two Strategies for Methicillin-resistant Staphylococcus Aureus (MRSA) Infection Prevention in Surgical Patients
Official title: An Interventional Study to Evaluate the Impact of Two Innovative Strategies in Preventing Nosocomial MRSA Infection in Surgical Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: MRSA Infection
Keywords: Staphylococcus aureus
Resistance
Prevention
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
Collaborators: name: European Commission
First posted: 2008-05-29
Enrollment: 126750
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study is a two-arm controlled multi-centre trial of two strategies to reduce nosocomial MRSA transmission and infection among surgical patients. Enrolment and primary analyses will be performed at the hospital level. A total of ten adult surgical departments with at least 3 surgical subspecialties each will participate in the study. Sites of the study are located in 9 countries (UK, France, Spain, Germany, Switzerland, Italy, Serbia, Greece and Israel).

The primary objective is to determine the effect of an early MRSA detection \& decolonization \& isolation strategy compared to an enhanced standard control strategy on healthcare-associated MRSA isolation rates among surgical patients at risk of MRSA carriage, who are hospitalized for at least 24 hours.


Eligibility criteria: Inclusion Criteria:

* Surgical patients with LOS\>24h

Exclusion Criteria:

* Surgical patients with LOS\<24h

Primary outcomes:
measure: Nosocomial MRSA isolation rate (expressed as the monthly rate of MRSA in clinical isolates divided by the number of susceptible patients per hundred)
timeFrame: Monthly
Secondary outcomes:
measure: Nosocomial MRSA infection rate (= number of nosocomial MRSA infections per 100 admissions)
timeFrame: Monthly
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Geneva University Hospitals
Study officials:
References:
citation: Lee AS, Cooper BS, Malhotra-Kumar S, Chalfine A, Daikos GL, Fankhauser C, Carevic B, Lemmen S, Martinez JA, Masuet-Aumatell C, Pan A, Phillips G, Rubinovitch B, Goossens H, Brun-Buisson C, Harbarth S; MOSAR WP4 Study Group. Comparison of strategies to reduce meticillin-resistant Staphylococcus aureus rates in surgical patients: a controlled multicentre intervention trial. BMJ Open. 2013 Sep 19;3(9):e003126. doi: 10.1136/bmjopen-2013-003126.
Clinical trial NCT06513767: A Clinical Investigation to Evaluate the Safety and Efficacy of Zirconia Ceramic Blocks for Use in Dental Prostheses.
Official title: A Prospective, Multicentre, Single-group, Target-value Clinical Investigation Evaluating the Safety and Efficacy of Zirconia Ceramic Blocks for All-ceramic Dentures for Use in Dental Prostheses.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Dental Prosthesis
Lead sponsor: Suzhou Kerui Medical Technology Co., Ltd
Sponsor class: OTHER
Collaborators: name: SHENZHEN XIANGTONG CO., LTD
First posted: 2024-07-22
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to use the investigational device (Zirconia Dental Ceramics) to perform dental prosthesis in Patients with permanent teeth. The main question it aims to answer is:

Is the safety and efficacy of the investigational device (Zirconia Dental Ceramics) adequate to meet the requirements for clinical use?

Participants will use the investigational device (Zirconia Dental Ceramics) to perform dental prosthesis and then complete a 12-month follow-up after prostheses. During the follow-up period，participants will assess their satisfaction，while the investigator will assess the efficacy indices of prosthesis survival rate, prosthesis success rate and prosthesis quality.

Detailed description: The study aims to provide clinical evidence for the use of the investigational product (zirconia dental ceramic) in dental restorations.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years old, gender is not limited;
2. Patients with permanent teeth who were judged by the investigator to be expected to have dental prostheses using zirconia materials;
3. Subjects volunteered and signed an informed consent form.

Exclusion Criteria:

1. Allergy to zirconia ceramic materials or a history of extensive allergies;
2. Patients with oral mucosal ulcers;
3. Patients presents with a significant, uncontrolled, systemic disease, encompassing, but not limited to, cardiovascular disease, endocrine or metabolic disease, and immune system disease, among others;
4. Pregnant or breastfeeding, or those planning to become pregnant during the investigation period;
5. Participation in another clinical investigation within 3 months;
6. Patients with mental disorders and a lack of autonomy;
7. Meets other conditions that, in the opinion of the investigator, make participation in this clinical investigation inappropriate.

Primary outcomes:
measure: Survival rate
timeFrame: Day 360
Secondary outcomes:
measure: Survival rate
timeFrame: Day 180
measure: Success rate
timeFrame: Day 180, Day 360
measure: Prostheses quality
timeFrame: Day 0, Day 180, Day 360
measure: Subject satisfaction
timeFrame: Day 0, Day 180, Day 360
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05550467: 24-hour Urinary Electrolyte Excretion in Chronic Kidney Disease
Official title: 24-hour Urinary Electrolyte Excretion and Renal Prognosis in Chronic Kidney Disease：a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Kidney Diseases
Electrolyte Imbalance
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2022-09-22
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Age ≥ 18 years, chronic kidney disease patients without kidney replacement therapy who had 24-h urine eletrocyte tests.

Brief summary: Association between excretion pattern and development trajectory of urinary electrolytes (urine sodium, urine potassium, urine chlorine, urine magnesium, urine calcium, urine phosphorus, urine creatinine, urea, uric acid, urine glucose, urine protein, urine retinol) and adverse prognosis in patients with chronic kidney disease


Eligibility criteria: Inclusion Criteria:

* Our study is a retrospective cohort study. The study included patients with adult（Age≥18years）CKD who were hospitalized in the Department of Nephrology, First Medical Center of Chinese PLA General Hospital from January 2014 to July 2022. Patients with CKD who had one or more 24-hour urinary electrolyte excretion tests at intervals of more than three months were included in the subgroup analysis.

Exclusion Criteria:

* Patients with hemodialysis therapy and urine volume less than 500ml were excluded.

Primary outcomes:
measure: Kidney disease progression
timeFrame: 2014.1.1-2022.7.31
measure: Death
timeFrame: 2014.1.1-2022.7.31
Secondary outcomes:
measure: Cardiovascular disease
timeFrame: 2014.1.1-2022.7.31
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00934167: Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients
Official title: NON CLINICAL INFERIORITY OF HEPARIN SODIUM PRODUCED BY HIPOLABOR FARMACEUTICA LTDA COMPARED TO THE HEPARIN SODIUM PRODUCED BY APP PHARMACEUTICALS IN VENOUS THROMBOEMBOLISM PROPHYLAXIS, IN SURGICAL PATIENTS WITH MEDIUM RISK FOR DEVELOPMENT OF THROMBOEMBOLISM.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Venous Thromboembolism
Lead sponsor: Azidus Brasil
Sponsor class: INDUSTRY
First posted: 2009-07-08
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study is to verify, through clinical examination and doppler, the non-inferiority of the drug test (heparin sodium 5.000UI/0.25 mL - HIPOLABOR) in relation to the drug compared (heparin sodium 5.000USP/mL - APP) in preventing the development of venous thromboembolism (VTE) in patients undergoing surgery for medium risk for the development of this pathology.


Eligibility criteria: Inclusion Criteria:

* Accept all items described in IC signing it in two ways;
* Be aged between 18 and 60;
* Be alert to the need for surgery antithrombotic prophylaxis;
* Be classified as "moderate risk" for developing VTE, according to the protocol of prophylaxis of deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery.

Exclusion Criteria:

* Acute coronary syndrome, it will make use of anticoagulation;
* Immobilization of the lower limbs due to fractures, because in this way will be considered as high risk;
* History of recent stroke;
* Patients at high risk of bleeding in which the use of heparin is contra-indicated;
* General Surgery in patients over 60 years in the case of patients at high risk for VTE;
* general surgery in patients 40 to 60 years with additional risk factors for development of VTE;
* Major amputations;
* More orthopedic surgeries;
* Patients with pre-surgical diagnosis of malignant neoplasms;
* Patients with a platelet level below 100x109 / L;
* Use of anticoagulants 48 hours before randomization;
* Severe liver failure;
* Be classified as "Low Risk" or "high risk" for developing VTE, according to Maffei et al. (2005);
* Pregnancy and lactation.

Primary outcomes:
measure: Non-appearance of venous thromboembolism
timeFrame: 2 h before the start of surgery, 1, 2, 3, 4, 5, 6, 7, 14, 21, 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Valinhos
country: Brazil
facility: Lal Clinica Pesquisa E Desenvolvimento Ltda
state: SP
Study officials:
References:
Clinical trial NCT03006640: Subcutaneous NTG for US Radial Artery Cannulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Morbid Obesity
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2016-12-30
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinicians are increasingly dealing with morbid obese patients. In morbid obese patients, difficult sampling and problems encountered with noninvasive blood pressure monitoring makes arterial cannulation an essential skill in many situations like surgeries or trans-radial procedures for coronary or carotid interventions.

Radial artery has been preferred over other sites for arterial cannulation due to low incidence of bleeding, better hemostats, more comfort, and immediate ambulation. sm In this study, subcutaneous nitroglycerin will be used to facilitate radial artery cannulation aiming to decrease insertion time, increase success rate and decrease related complications


Eligibility criteria: Inclusion Criteria:

* morbid obese indicated for radial artery cannuulation

Exclusion Criteria:

* +ve allen test peripheral arterial disease refusal

Primary outcomes:
measure: Success rate
timeFrame: 24 hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04561440: Copy Number Variation in Prenatal Diagnosis
Official title: Copy Number Variation in Prenatal Diagnosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Copy Number Variation
Genome
Lead sponsor: Taizhou Hospital
Sponsor class: OTHER
First posted: 2020-09-23
Enrollment: 16000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: total population need invasival prenatal diagnosis, which including total pregnant women whose aged over than 35 in Taizhou City of East China.

Brief summary: An observed study is aim to map the CNVs distribution in human genome of Chinese prenatal population.

Setting: Prenatal diagnosis center of Taizhou City, Zhejiang Province Patient: total cases of pregnant women needed prenatal genetic diagnosing Methods: karyotype was performed with combined of molecular and cytogenic protocol. Subgroup: molecular karyotyping performed by genomic Chip (CMA) or NGS, the latter including cnv-seq and NIPT.

Main outcome: comparison of CNVs distributions in subgroups. Second outcome: comparison of CNVs distributions in demographic dates.


Eligibility criteria: Inclusion Criteria:

* total population need invasival prenatal diagnosis

Exclusion Criteria:

* multipara

Primary outcomes:
measure: comparison of CNVs distributions in subgroups
timeFrame: 2016-2020
Secondary outcomes:
measure: comparison of CNVs distributions in demographic dates.
timeFrame: 2016-2020
Other outcomes:
Locations:
city: Taizhou
country: China
facility: Taizhou Hospital of Zhejiang province
state: Zhejiang
Study officials:
References:
Clinical trial NCT05251740: Impact of a Standing Program in a Child With Spina Bifida: A Case Report
Official title: Impact of a Standing Program in a Child With Spina Bifida: A Case Report
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spina Bifida With Hydrocephalus
Lead sponsor: University of St. Augustine for Health Sciences
Sponsor class: OTHER
First posted: 2022-02-23
Enrollment: 1
Sex: FEMALE
Minimum age (years): 9
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single participant case study
Primary purpose: TREATMENT

Brief summary: The purpose of this case study is to investigate a child with MMC who has significant knee and hip flexion contractures to answer the following research questions: 1) Is a home standing program effective in reducing hip and knee flexion contractures in a child with MMC? 2) Does a home standing program result in a change in the quality of functional movement?

A Physical therapist, PT, will administer the Peds NRS and goniometric measurements prior to the start of the study and at the end of the study. The PT will also provide the parent instruction on the standing home program with weekly check-ins to ensure the parent and child are able to follow the home program. The home standing program will last 8 weeks. The parent will keep a written log of stander use. The Peds NRS scores and goniometric measurements will be compared pre and post intervention. The expected outcome is that the Peds NRS scores and hip and knee extension range of motion measurements will improve.


Eligibility criteria: Inclusion Criteria:

* diagnosis of Spina Bifida
* be able to stand with an assistive device

Exclusion Criteria:

* a diagnosis unrelated to Spina Bifida that limits standing
* medical restrictions that contraindicate standing

Primary outcomes:
measure: Goniometric measurements
timeFrame: At 0 weeks
measure: Goniometric measurements
timeFrame: At 8 weeks
measure: Pediatric Neuromuscular Recovery Scale (Peds NRS)
timeFrame: At 0 weeks
measure: Pediatric Neuromuscular Recovery Scale (Peds NRS)
timeFrame: At 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: San Marcos
country: United States
facility: University of St. Augustine
state: California
Study officials:
References:
Clinical trial NCT04835740: Effects of High-intensity Interval Aerobic Training on Balance, Walking Capacity, and Quality of Life in Patients With Sub-acute Stroke
Official title: Effects of High-intensity Interval Aerobic Training on Balance, Walking Capacity, and Quality of Life in Patients With Sub-acute Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke, Ischemic
Cerebrovascular Accident
Keywords: Cerebrovascular accident
Treadmill Training
High-intensity interval training
Walking capacity.
Lead sponsor: Akhtar Saeed Medical and Dental College
Sponsor class: OTHER
First posted: 2021-04-08
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hemiplegia is one of the most common sequelae of stroke. Stroke is the leading cause of disability in adults all around the world. Stroke survivors can suffer several neurological impairments and deficits which have an important impact on patient's quality of life and which increase the costs for health and social services. After stroke, impairments in ADLs and functional status, deterioration in health related quality of life can be seen.

The purpose of this study is to Determine the effect of Aerobic exercise training on Balance, Walking capacity and quality of life in sub-acute stroke.


Eligibility criteria: Inclusion Criteria:

* 18 to 75 years of age.
* Ischemic Stroke that occurred in the recent 3 months.
* Who can walk independently or by using assistive device.
* Have a minimum Chedoke McMaster Stroke Assessment (CMSA) leg impairment score of 3 but less than 7.

Exclusion Criteria:

* Patients were excluded from the study if they have a stroke that occurs more than 3 months.
* Hemorrhagic Stroke.
* If resting blood pressure more than 160/100 even after taking medications
* Have by-pass surgery in recent 3 months.
* Other musculoskeletal problems which restrict the patient's ability to do aerobic activity.

Primary outcomes:
measure: 6 Minute walk Test
timeFrame: 5 weeks
Secondary outcomes:
measure: Berg Balance test and rating scale
timeFrame: 5 weeks
measure: Stroke Impact scale
timeFrame: 5 weeks
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Akhtar Saeed Hospital
Study officials:
References:
Clinical trial NCT01869140: the Hypoalgesic Effect of Spinal Manual Therapy
Official title: the Hypoalgesic Effect of Spinal Manual Therapy on an Healthy Population: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Back Pain
Lead sponsor: Institut Franco Europeen de Chiropratique
Sponsor class: OTHER
First posted: 2013-06-05
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: To study the immediate effect of spinal manual therapy on pain perception in normal subjects

Detailed description: Is this effect only local or is it also noticed away from the stimulated area? How long does it last? Is there a dose/response phenomenon?

Eligibility criteria: Inclusion Criteria:

Healthy Students who volunteer from Murdoch University

-

Exclusion Criteria:

* contraindication to spinal manual therapy

Primary outcomes:
measure: the Pressure pain threshold in KPa/Cm2 will be measure with an Algometer (SOMEDIC)
timeFrame: the pressure pain threshold will be measure immediately after intervention and every 15 minutes during 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Perth
country: Australia
facility: Murdoch University
state: Western Australia
Study officials:
affiliation: Institut Franco Europeen de Chiropratique
name: yannick audo, PhD student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00205140: Effect of Pharmacist Initiated Recommendations On Prescribing For Participants In the Senior MEDS Personalized Medication Review
Official title: Participant Characteristics, Medication Utilization, and the Effects of Pharmacist Initiated Recommendations On the Prescribing For Participants In the Senior MEDS Personalized Medication Review for Adults Age 55 and Older
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Healthy
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 100
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes

Brief summary: What are the demographic and medication utilization characteristics of participants in the Senior MEDS personalized medication review compared to other community-dwelling elderly, what is the level of satisfaction with Senior Meds, and does the Senior Meds program lead to changes in the participants' drug regimen?


Eligibility criteria: Inclusion Criteria:

* 55 or older

Exclusion Criteria:

* 54 or younger

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Robert M Breslow, RPh, BCPS
role: PRINCIPAL_INVESTIGATOR
References: